Login to Your Account

AtheroGenics Seeks New Partner As AGI-1067 Begins Diabetes Trial

By Jennifer Boggs

Friday, August 24, 2007
Four months after losing partner AstraZeneca plc upon mixed cardiovascular data, AtheroGenics Inc. plans to start looking for a new collaborator, as patient enrollment gets underway in a Phase III trial of its oral anti-inflammatory antioxidant drug, AGI-1067, in diabetes.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription